Lozapine

Quick links to important sections

Lozapine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lozapine

Quick Facts: Lozapine

Property Description
Active ingredient Clozapine
Form Tablet, Orally Disintegrating Tablet (ODT), Oral Suspension
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Common use Management of schizophrenia
Origin Synthetic tricyclic dibenzodiazepine derivative

What is Lozapine? Defining the Atypical Antipsychotic

Lozapine is a potent, prescription-only psychotropic agent whose active component is the substance Clozapine, used to modulate mental processes. This medicine is a synthetic compound, chemically classified as a tricyclic dibenzodiazepine derivative, defining its unique structure. Its classification as a second-generation antipsychotic offers a different receptor binding profile compared to older agents. Clozapine is a single-agent product responsible for all its pharmacological effects.


What Pharmacological Class Does Lozapine Belong To?

Lozapine belongs to the atypical antipsychotic class, a grouping that reflects its complex interaction with neurotransmitter systems beyond simple dopamine blockade. The drug is administered via the oral route, typically supplied as standard tablets, but it is also distinguished by its availability in specialized forms like orally disintegrating tablets (ODT) and an oral suspension. This range of preparations addresses the diverse needs of patients who may struggle with solid medication intake.


What is the General Purpose of Clozapine?

The general purpose of Clozapine is to help stabilize and regulate the brain's complex neural networks by adjusting the activity of key chemical messengers, such as dopamine and serotonin. This medication is reserved for the management of severe mental health conditions, primarily in patients diagnosed with schizophrenia. Its distinguishing factor is its use when individuals are classified as treatment-resistant or severely ill and have not achieved adequate response with other standard antipsychotic treatments.

Regulatory References

  1. World Health Organization

What side effects are possible with Lozapine?

The safety profile of Lozapine (Clozapine) is defined by officially documented adverse reactions classified by frequency and system-organ class, with several risks warranting prominent regulatory warnings.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Very Common Drowsiness, sedation, tachycardia (fast heart rate), dizziness, hypersalivation, and constipation.
Common Weight gain, tremor, headache, blurred vision, hypotension (low blood pressure), and fever.

Serious adverse reactions are prominently documented in regulatory text, including the risk of Agranulocytosis (severe reduction in white blood cells), which can be fatal. Other serious events involve the cardiac system (Myocarditis, Cardiomyopathy, Orthostatic Hypotension leading to syncope), and the neurological system (Seizures and Neuroleptic Malignant Syndrome [NMS]).

These reactions affect major System-Organ Classes, specifically the Blood and Lymphatic System, Cardiac Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Safety-Related Context

Safety notes explicitly documented by regulatory authorities include time-related patterns, such as the risk of agranulocytosis being highest during the first 18 weeks of treatment, and the risk of Orthostatic Hypotension being greatest during the initial titration period.

Safety-Related Limitations: The use of Clozapine is restricted, and its administration is subject to mandated safety measures, including the requirement for regular Absolute Neutrophil Count (ANC) monitoring to mitigate the life-threatening hematological risks. Furthermore, a statement on increased mortality is documented for older adult patients with dementia-related psychosis.

Overdose and Emergency Response

A Lozapine (Clozapine) overdose is formally documented by regulatory authorities to present with severe neurological and cardiovascular manifestations. Documented clinical signs include profound CNS depression, which may range from drowsiness and delirium to coma and the occurrence of seizures. Overdose also impacts the cardiovascular system, leading to signs such as tachycardia (rapid heartbeat) and hypotension (low blood pressure), as well as respiratory depression and hypersalivation.

The official regulatory profile identifies potential life-threatening outcomes including mortality, aspiration, and the risk of delayed cardiac arrhythmias.

Regulatory guidance states that immediate medical attention must be sought if an overdose is suspected. Management is strictly symptomatic and supportive, as no specific antidote is known. Due to the documented risk of delayed complications, including cardiac effects, regulatory authorities mandate that patients receive continuous cardiac monitoring and close medical supervision for at least five days following the event. Specific procedural notes include the option for gastric lavage or administering activated charcoal within the first six hours, and the instruction to avoid using epinephrine to treat associated hypotension.

Therapeutic Uses of Lozapine

Lozapine is used to manage acute episodes and distressing symptoms across specific, severe conditions where supportive management is appropriate and functional stability is affected.


Therapeutic Scope and Benefits

Lozapine is primarily used for patients whose symptoms of schizophrenia—including delusions, hallucinations, and disorganized thinking—are classified as treatment-resistant. Lozapine plays a role in managing the chronic risk of recurrent suicidal thoughts and behavior in patients with schizophrenia or schizoaffective disorder. In these complex cases, Lozapine provides strong symptomatic support to assist with maintaining functional stability.

The medication is also commonly selected when a patient is highly prone to disabling extrapyramidal symptoms (involuntary movements) from other standard treatments. This provides symptom relief and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Persistent Symptoms
Primary Use Context Used in situations involving certain distressing symptoms across conditions where functional stability becomes affected.
Key Symptom Domain Positive and Negative symptoms of psychosis; recurrent suicidal behavior.
Patient Benefit Focus Provides support that helps ease the overall symptom burden and contributes to improved comfort.

Eligibility and Restrictions for Use

Lozapine (Clozapine) is a highly restricted medication reserved for specific adult populations and is defined by strict non-eligibility rules, primarily due to the risk of severe blood disorders.

Contraindicated Populations

Use is contraindicated (must not be used) for patients with a history of Clozapine-induced agranulocytosis or pre-existing severe blood disorders. It is also contraindicated in older adults with dementia-related psychosis, patients with severe active liver disease, uncontrolled epilepsy, or severe gastrointestinal hypo-motility (paralytic ileus).

Age and Eligibility Restrictions

  • Adults are the approved population, specifically for treatment-resistant schizophrenia or reducing the risk of recurrent suicidal behavior.
  • Pediatric Use: Safety and effectiveness are not established in children and adolescents, and use is generally not recommended.
  • Geriatric Use: Requires caution, and is contraindicated for dementia-related psychosis.

Conditional Use Requirements

Treatment is restricted to patients who meet the required baseline Absolute Neutrophil Count (ANC) thresholds (typically ge 1500/mu L) and are able to comply with mandatory regular ANC monitoring. Caution is required when used in patients with pre-existing cardiovascular disease or hepatic/renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Lozapine (Clozapine) is structured around prohibited combinations and substances that modify drug exposure or create additive system effects.

Interaction-Related Restrictions

Classification Examples of Interacting Substances/Categories
Contraindicated Combinations Bone marrow suppressants (e.g., Carbamazepine, cytotoxic agents), long-acting depot antipsychotic injections, and Paxlovid (Nirmatrelvir/Ritonavir).
Pharmacokinetic Modifiers Fluvoxamine (strong CYP1A2 inhibitor) significantly increases plasma concentrations, requiring a dose reduction. Inducers like Rifampicin or Phenytoin may decrease exposure and are not recommended.
Pharmacodynamic Effects Alcohol and Benzodiazepines create additive CNS depression and may increase the risk of respiratory arrest. Anticholinergics can potentiate severe anticholinergic toxicity.

Official Interaction Statements

Co-administration with agents that substantially suppress bone marrow is absolutely prohibited due to the risk of agranulocytosis, a restriction explicitly defined in regulatory documents. Pharmacokinetic interactions predominantly involve the CYP1A2 enzyme; the cessation of Tobacco Smoke (a CYP1A2 inducer) is associated with an increase in Lozapine plasma levels, requiring dose consideration. Furthermore, Lozapine may increase the plasma concentration of highly protein-bound drugs such as Warfarin and Digoxin via protein displacement. Special caution is noted for elderly patients and those with hepatic or renal impairment, who are at increased susceptibility to adverse effects from co-administered agents.

Mechanism of Action

How Lozapine Works

Lozapine acts primarily in the central nervous system by binding to and blocking multiple neurotransmitter receptor sites. The drug functions as an antagonist at both the Dopamine D2 and the Serotonin 5-HT2 A receptors. This interaction modifies the signaling patterns of these neurotransmitters in brain regions associated with cognitive and emotional processing, resulting in altered downstream neurotransmission within targeted neural circuits.

Additionally, Lozapine acts as an antagonist at several other receptor types, including Histamine H1 and alpha1-adrenergic receptors. Antagonism at the H1 receptor alters signaling mediated by histamine, which influences states of arousal. alpha1-adrenergic antagonism modifies aspects of autonomic regulation. These collective receptor interactions define the drug's overall profile of physiological modulation.

Dosage and Administration Information

Administration Guidelines for Lozapine

Lozapine is administered exclusively via the oral route, available as standard tablets, an oral suspension, and orally disintegrating tablets (ODT). The entire process of use is defined by a highly structured protocol, which focuses on safe and predictable dose adjustment.


Official Administration and Dosing Protocol

Category Instructions
Initiation and Titration Therapy must begin with a low starting dose of 12.5 mg once or twice daily. The dose is then gradually increased in small increments of 25 mg to 50 mg per day.
Maintenance Dose Range The typical range for continued use is 300 mg to 450 mg per day, with the established maximum daily dosage limited to 900 mg.
Dosing Frequency The total daily amount is usually administered in divided doses, with the largest portion often taken at bedtime. Doses of 200 mg or less may be taken once daily.
Context of Intake The medicine can be taken with or without food. Oral suspension must be shaken well and measured precisely.
Administration Prerequisite The initiation and continuation of Lozapine are strictly subject to a mandatory schedule of laboratory testing.
Interruption Rule If administration is stopped for 48 hours or longer, the patient must re-initiate treatment at the lowest starting dose (12.5 mg) and undergo a new titration process.
Older Adults For geriatric patients, a lower starting dose (12.5 mg) is required, and the subsequent titration must proceed more slowly.

Procedural Structure

The usage of this medication follows a structured protocol that governs every phase of use, beginning with a mandatory procedural clearance required prior to administration. The use pattern is defined by a slow, cautious titration schedule to reach the therapeutic range, and strict rules for frequency. This protocol is maintained by a specific re-initiation rule that mandates a return to the lowest dose following any significant break in therapy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lozapine

Research on Lozapine spans several decades, with studies focused on the study of conditions characterized by fluctuating or episodic manifestations. The body of evidence includes rigorous Randomized Controlled Trials (RCTs) and various other types of research that contribute to the broader evidence landscape used by regulators to understand the medicine.


Evidence for use in Treatment-Resistant Schizophrenia

This section summarizes the structure of clinical research, including randomized controlled trials and large meta-analyses, that evaluated outcomes like symptom change and measures of functional capacity in patients whose condition had not improved with other treatments.

Research has examined Lozapine within a specific population of adults diagnosed with schizophrenia who are categorized as treatment-resistant. Studies monitored outcomes reflecting daily functioning or activity level and tracked long-term measurements such as rehospitalization rates.

Research described patterns in the evolution of symptom measurements compared to controls where, in this treatment-resistant group, certain symptom scores was observed. The evidence base is substantial. However, inconsistency in definitions of treatment resistance has been noted across some older research, which has been noted as a contributor to variability across studies.


Evidence for use in Reducing Recurrent Suicidal Thoughts and Behavior

This section will detail the specific, targeted research, including key two-year randomized studies, that examined the frequency of suicidal ideation and suicide attempts in patients with schizophrenia or schizoaffective disorder.

Studies monitored outcomes such as the measured frequency of both suicide attempts and suicidal ideation, as well as tracking episodes requiring urgent intervention or hospitalization. This research contributes to the broader evidence landscape by providing data on this specific outcome, providing specific data on this outcome not commonly evaluated in all standard treatment trials.

The existing research is focused on the population with recurrent risk and provides limited insight into whether the medicine is applicable for primary prevention. Sample sizes were modest in some studies, leading to limited statistical power for conclusions about the outcome of completed suicide.


What is Still Uncertain About Lozapine Research

Comparative evidence is lacking in several areas, particularly concerning direct, long-term comparisons against newer antipsychotics in the treatment-resistant population. There is limited information for long-term outcomes regarding the sustained maintenance of functional capacity over many years. Studies help show what has been observed so far, but research provides context but not individual predictions about how any single person will respond.

Key Studies & References

  1. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline NG235)

Frequently Asked Questions (FAQ)

Common questions about Lozapine (FAQ)

Q: What is the main difference between Lozapine and other common similar medications?

A: Official information defines Lozapine’s primary role as treatment for certain people with schizophrenia whose condition has not improved with standard treatments. This specific, approved indication for treatment-resistant schizophrenia, supported by clinical evidence, is the main defining factor mentioned in regulatory documents compared to other similar medications.

Q: Is Lozapine used for long-term treatment?

A: Yes, Lozapine is indicated for the long-term management of chronic conditions like schizophrenia. Studies supporting the indication for reducing the risk of recurrent suicidal thoughts and behavior monitored patients over a period of two years, demonstrating its role in sustained care.

Q: Does Lozapine cause weight gain for most people?

A: Regulatory documents list weight gain as a common adverse reaction, meaning it has been reported to occur in at least 1 out of 100 people but fewer than 1 out of 10 people in clinical trials. Due to this potential effect, official guidance often recommends clinical monitoring of weight throughout the course of treatment.

Q: How quickly should I expect Lozapine to start working?

A: The primary clinical trials showing effectiveness for treatment-resistant schizophrenia were typically evaluated over six weeks. The initial dosage is adjusted gradually (titrated) over the first few weeks, and this initial period of adjustment is often associated with the process of establishing the medicine's presence in the body.

Q: Is Lozapine the same type of drug as a benzodiazepine?

A: No. Lozapine (Clozapine) is classified as an atypical antipsychotic drug, a class used to modulate mood and thought processes. While its chemical structure is a complex derivative that contains a 'diazepine' component, it is a distinct pharmacological class from benzodiazepine drugs.

Q: If I miss a dose of Lozapine, what's the general advice?

A: If a dose is missed for more than 48 hours (two days or longer), regulatory documents state that treatment must be re-started at the lowest dose with a new gradual adjustment phase (re-titration). Guidance for a single missed dose may differ from the protocol for interruptions of 48 hours or longer, which mandates re-starting at the lowest dose.

Q: Can Lozapine be taken by someone with high blood pressure?

A: Caution is advised for people with pre-existing cardiovascular disease. Regulatory information notes that Lozapine should be used carefully in those taking antihypertensive medications (drugs for high blood pressure) because it has the potential to cause low blood pressure (hypotension) as a side effect, and official information notes the importance of a comprehensive medical assessment before use.

Q: Is Lozapine safe to take with common pain relievers like ibuprofen?

A: Regulatory documents do not specifically mention ibuprofen or similar common pain relievers as a direct interaction. However, caution is advised with any drug that could affect bone marrow, and official information indicates that a comprehensive review of all medications is important.

Q: Can Lozapine affect how birth control works?

A: Some hormonal contraceptives (birth control) may increase the plasma concentration of Lozapine in the blood. This effect happens because the birth control can affect the enzymes (like CYP1A2) that break down Lozapine, potentially leading to more pronounced effects or side effects.

Q: What should I do if a side effect feels severe?

A: Official documentation emphasizes that the occurrence of symptoms like fever, severe fatigue, or a fast heartbeat may be associated with serious documented adverse reactions. Regulatory documents describe numerous severe side effects that require immediate attention.

Q: Can Lozapine cause changes in mood or personality?

A: The medicine acts on the central nervous system, which is involved in mood and emotional processing. Officially documented side effects include central nervous system disturbances such as seizures, confusion, agitation, or delirium, which reflect significant alterations in mental state. Anxiety is also listed as a less common side effect.

Q: Are there any restrictions on driving or operating machinery while taking Lozapine?

A: Yes, official patient information advises caution regarding activities requiring mental alertness, such as driving or operating heavy machinery. This caution is due to the potential for side effects like drowsiness, sedation, and dizziness, especially during the initial phase of treatment.

Q: What if I'm currently taking a supplement like St. John's Wort? Can I take Lozapine?

A: Official documents describe that the use of strong CYP3A4 inducers like St. John's Wort may lead to a decrease in the medicine’s level in the blood. These substances can increase the speed at which Lozapine is broken down, potentially leading to a reduced effect.

Q: Does Lozapine affect sleep patterns?

A: Drowsiness and sedation are very common side effects. Beyond this, studies indicate that the medicine can sometimes be associated with improved sleep quality and increased total sleep time, although insomnia has also been reported as a documented side effect.

Q: Can people with liver or kidney issues use Lozapine?

A: The medicine is contraindicated (must not be used) in people with severe active liver disease. For patients with existing hepatic (liver) or renal (kidney) impairment, caution is necessary, and a dosage reduction may be required to manage the increased risk of adverse effects.

Q: Does taking Lozapine with food change how it works?

A: Official administration instructions state that Lozapine can be taken with or without food. While food may slightly influence the absorption of the drug, these changes are generally regarded as not clinically significant according to regulatory pharmacokinetics studies.

Q: Can men and women expect different side effects from Lozapine?

A: Some official research and surveillance data suggest that there may be sex-based differences in adverse effects. For instance, official data has suggested that differences in certain adverse effects, such as neutropenia and metabolic issues, have been observed in studies.

Q: Is Lozapine a controlled substance?

A: Lozapine (Clozapine) is not classified as a controlled substance under the U.S. Controlled Substances Act. However, due to its profile of serious safety risks, it is a prescription-only medicine that requires highly restricted distribution and monitoring programs.

Q: Can Lozapine interact with caffeine?

A: Caffeine is known to inhibit the enzyme (CYP1A2) primarily responsible for breaking down Lozapine. An increase in caffeine intake may therefore increase the medicine’s concentration in the body, which could potentially lead to more side effects.

Q: Does Lozapine cause dry mouth?

A: Although hypersalivation (excessive salivation) is a very common side effect, dry mouth is also officially listed as a documented, but less frequent, adverse reaction. This is related to the drug’s complex receptor actions.

Q: What is the risk of discontinuing Lozapine suddenly?

A: Regulatory warnings state that abrupt discontinuation may be associated with the rapid return of psychotic symptoms. Furthermore, patients may experience withdrawal symptoms, which can include signs of 'cholinergic rebound' such as sweating, headache, nausea, and vomiting.

Q: Are there known withdrawal symptoms if Lozapine is stopped?

A: Yes, official documents advise monitoring patients for withdrawal symptoms when the medicine is stopped. Documented symptoms can include signs like profuse sweating, headache, nausea, vomiting, and diarrhea, related to a phenomenon called cholinergic rebound.

Q: What does the term 'off-label use' mean for Lozapine?

A: The term off-label use refers to using a medicine for a purpose, patient population, or dosage that is not explicitly approved and detailed in the official regulatory documents. This use is based on the judgment of a healthcare provider rather than a formal regulatory approval.

Q: Can Lozapine make existing anxiety worse initially?

A: Anxiety is listed as a less common side effect reported during clinical trials. The drug affects brain chemistry associated with mental state, but the labeling does not specifically confirm whether pre-existing anxiety is worsened during the initial phase of treatment.

Q: Is it common to need a dosage adjustment after starting Lozapine?

A: Yes, regulatory instructions require a slow, gradual increase in dosage, known as titration, to reach the effective maintenance dose. Adjustments may also be needed later on for people with specific issues like liver or kidney impairment or when beginning or stopping certain interacting medicines.

Q: Is it normal to feel dizzy or lightheaded when first taking Lozapine?

A: Yes, these are common side effects. The risk of dizziness, lightheadedness, and low blood pressure (orthostatic hypotension) is documented to be highest during the initial titration period—the time when the dose is first being increased.

Q: Is it okay to take Lozapine if I'm already taking supplements for sleep?

A: Due to the risk of additive CNS depression (increased sedation), official guidance advises caution when taking Lozapine with other substances that cause drowsiness. This principle applies generally to many substances, including supplements, that affect the central nervous system.

How should Lozapine be stored and disposed of?

How to Store and Dispose of Clozapine (Lozapine)

Clozapine (Lozapine) must be stored under specific conditions defined by regulatory labeling to maintain stability.


Storage Requirements

Clozapine tablets require storage at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), and should be kept in a tight container protected from moisture. The oral suspension must be protected from light and must not be refrigerated or frozen. After initial opening, the oral suspension remains stable for 100 days. All forms of this medication must be stored out of the reach of children.


Disposal Instructions

Unused or expired medication should not be flushed down a toilet or poured down a drain. Disposal should preferably be handled through a drug take-back program. If a program is unavailable, follow regulatory guidance to mix the product with an undesirable substance, seal it in a container, and discard it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lozapine found in:

A-Z Index: